Drug
Prexasertib clinical trials
Also written LY2606368.
- studies test it
- 16
- open now
- 1
- in phase 3
- 0
- first study started
- 2010
Keep track of what changes. Save the prexasertib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Combined with it in one product
Studies by the year they started
16 studies that test it; most in 2016 (5)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2015 | 2 |
| 2016 | 5 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 3 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 10
- Phase 2
- 7
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 10
Eli Lilly and Company (6) · Dana-Farber Cancer Institute (3) · Memorial Sloan Kettering Cancer Center (1) · Children's Oncology Group (1) · M.D. Anderson Cancer Center (1) · Baylor Research Institute (1) · Geoffrey Shapiro, MD, PhD (1) · H. Lee Moffitt Cancer Center and Research Institute (1)
Often tested with
Tested in the same studies.
Cytarabine (2) · Irinotecan (1) · Fludarabine phosphate (1) · Fludarabine (1) · LY3023414 (1) · Olaparib (1) · LY3300054 (1) · Ralimetinib (1)
Studies
Open first, then newest update. How each study uses prexasertib is read from its arms, and is right about nine times in ten.
Testing it · 16
- A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCCRecruitingPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT06597565Written as ACR-368
- A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and RhabdomyosarcomaCompletedPhase 1/2Memorial Sloan Kettering Cancer CenterNCT04095221Written as Prexasertib
- Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid TumorsCompletedPhase 1Children's Oncology GroupNCT02808650Written as Prexasertib
- Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeCompletedPhase 1M.D. Anderson Cancer CenterNCT02649764Written as Prexasertib
- LY3023414 and Prexasertib in Metastatic Triple-negative Breast CancerCompletedPhase 2Baylor Research InstituteNCT04032080Written as Drug 1: LY3023414; Drug 2: Prexasertib
- A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair DeficiencyCompletedPhase 2Dana-Farber Cancer InstituteNCT02873975Written as LY2606368
- A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate CancerTerminatedPhase 2National Cancer Institute (NCI)NCT02203513Written as LY2606368
- A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian CancerCompletedPhase 2Eli Lilly and CompanyNCT03414047Written as Prexasertib
- Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid TumorsCompletedPhase 1Geoffrey Shapiro, MD, PhDNCT03057145Written as Prexasertib
- A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid TumorsCompletedPhase 1Dana-Farber Cancer InstituteNCT03495323Written as Prexasertib
- A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung CancerCompletedPhase 2Eli Lilly and CompanyNCT02735980Written as Prexasertib
- A Study of Prexasertib (LY2606368) in Participants With Advanced CancerCompletedPhase 1Eli Lilly and CompanyNCT02778126Written as [¹⁴C]Prexasertib
- Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I TrialTerminatedPhase 1Dana-Farber Cancer InstituteNCT03735446Written as Prexasertib
- A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic CancerCompletedPhase 1Eli Lilly and CompanyNCT02860780Written as prexasertib
- A Study of Prexasertib (LY2606368) in Japanese Participants With Advanced CancersCompletedPhase 1Eli Lilly and CompanyNCT02514603Written as Prexasertib
- A Phase 1 Study in Participants With Advanced CancerCompletedPhase 1Eli Lilly and CompanyNCT01115790Written as Prexasertib
Given in every arm · 4 — prexasertib is usual care beside what is tested
- A Phase 2 Study of ACR-368 in Endometrial AdenocarcinomaRecruitingPhase 2Acrivon TherapeuticsNCT05548296Written as ACR-368
- Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain TumorsCompletedPhase 1St. Jude Children's Research HospitalNCT04023669Written as Prexasertib
- A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced CancerCompletedPhase 1Eli Lilly and CompanyNCT02124148Written as Prexasertib
- A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck CancerCompletedPhase 1Eli Lilly and CompanyNCT02555644Written as Prexasertib
Codes
What other systems call prexasertib · ClinicalTrials.gg INT000469
- MeSH (NLM) C000608121prexasertibOne source ClinicalTrials.gov
- UNII (FDA) 820NH671E6PREXASERTIBConfirmed FDA, Wikidata
- Wikidata Q27269284prexasertibConfirmed FDA, Wikidata
- NCI Thesaurus C91392PrexasertibOne source FDA
- DrugBank DB12008One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000608121 | prexasertib | One source ClinicalTrials.gov |
| UNII (FDA) | 820NH671E6 | PREXASERTIB | Confirmed FDA, Wikidata |
| Wikidata | Q27269284 | prexasertib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C91392 | Prexasertib | One source FDA |
| DrugBank | DB12008 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.